Bymetric
UK company intelligence
Company Active LTD

Company profile

Medicines Evaluation Unit Limited

UK company 03779957, incorporated on 28 May 1999.

Medicines Evaluation Unit Limited is a UK company with status Active founded in 1999 based in South East England.

Company number
03779957
Incorporated
28 May 1999
Companies House status
Active

Company identity

Founded / incorporated
28 May 1999

Company number 03779957

Verify at Companies House
Legal name
MEDICINES EVALUATION UNIT LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
3 FORBURY PLACE
23 FORBURY ROAD
READING
UNITED KINGDOM
UNITED KINGDOM
RG1 3JH
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

4 levels 1 ultimate controller
1
Company Active LTD
Medicines Evaluation Unit Limited
CRN 03779957
2
Direct controller Active LTD
Iqvia LTD.
CRN 03022416
3
Intermediate controller Active PRIVATE-UNLIMITED
Iqvia Rds Holdings
CRN 02703164
4
Intermediate controller Active LTD
Iqvia Rds UK Holdings LTD.
CRN 07067763
5
Ultimate controller
06171073
CRN 06171073

Company events

Reference milestones and recent Companies House filing stream events.

6 events
11 Jun
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

10 Jun
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzUyNjIwMDY5MGFkaXF6a2N4

Published 10 Jun 2026 11:24

28 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

28 May
1999

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2012
Funded years
2012
Age at first award
12 years

Projects

2012 Knowledge Transfer Partnership

The University of Manchester And Medicines Evaluation Unit Limited

1 May 2012 to 30 Sep 2014

Awarded
Unknown

To develop and implement a programme of PROMS which underpin the identification of phenotypes for chronic obstructive pulmonary disease and the delivery of stratified medicines.

Product types

Knowledge Transfer Partnership